COO Susanna Gatti sells 39,950 shares at $35.09 avg ($1.4M) following heavy insider selling pattern at unprofitable biotech
Susanna Gatti, Chief Operating Officer of Dyne Therapeutics, executed 2 separate sales totaling 40.0K shares for $1,401,901.66 on 2024-06-21 and 2024-06-24, reducing her post-transaction holdings to 148.8K shares (-21.2% from pre-transaction). This sale follows five additional insider sales at DYN within the preceding 11 days (2024-06-10 through 2024-06-12), indicating a sustained divestment pattern by senior management. The timing is notable: the stock has risen 14.1% over 30 days and 33.0% over 90 days, tracking near its 52-week high of $35.63, yet the company remains unprofitable with net income of $-65.6M over its most recent full fiscal year. The concentrated sale activity across multiple executives during a period of stock strength in an unprofitable organization warrants examination of the motivation and timing context underlying these transactions.